Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag164 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, online erschienen am 28.04.2026. Verfasst von Lili Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Clear Cell, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy, Ovarian Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Ovarian clear cell carcinoma (OCCC) frequently exhibits resistance to conventional chemotherapy with limited treatment options. This study reports a heavily pretreated advanced case with liver metastases to investigate the efficacy of gemcitabine combined with PD-1 inhibitor in such refractory patients.
Methods
We present a case of stage IIIC OCCC that progressed after first-line platinum-based chemotherapy. The patient was treated with gemcitabine in combination with the PD-1 inhibitor toripalimab. Genetic alterations were analyzed using next-generation sequencing, and PD-L1 expression was assessed by immunohistochemistry (combined positive score [CPS]). Treatment response and safety profiles were regularly monitored.
Results
The combination therapy induced a complete remission lasting over 24 months, with a manageable safety profile. Molecular profiling revealed a loss-of-function mutation in ARID1A, which may enhance tumor sensitivity to gemcitabine, while elevated PD-L1 expression (CPS = 30) may serve as a predictive biomarker for immunotherapy response in OCCC. Notably, the deep and durable clinical response observed suggests a potential synergistic effect between gemcitabine and immunotherapy, wherein ARID1A deficiency-induced chemosensitivity may prime the tumor microenvironment for enhanced immune checkpoint inhibition, offering a compelling rationale for this combination strategy in platinum-resistant OCCC.
Conclusion
This study proposes a promising therapeutic strategy for advanced OCCC and supports the clinical value of molecular profiling-guided treatment. Both ARID1A status and PD-L1 expression warrant further validation as potential biomarkers in prospective clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, China.
ORCID-Profile: Xiangkai Meng
Zitieren
APA
Wang, L., Chen, X., Li, Y., Chang, H., & Meng, X. (2026). Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag164
Vancouver
Wang L, Chen X, Li Y, Chang H, Meng X. Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag164
BibTeX
@article{Wang2026,
author = {Wang, Lili and Chen, Xinyang and Li, Yuanyuan and Chang, Hua and Meng, Xiangkai},
title = {Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag164}
}
EUVIMED